China suspends major platform that doubted Beijing COVID policies

Dingxiang Yuan posted articles debunking use of traditional medicine for virus

20220810 DXY

Now-suspended DXY, backed by tech giant Tencent, has at least 30 million followers on China's three major social apps.

CISSY ZHOU, Nikkei staff writer

HONG KONG -- China has suspended a health platform followed by tens of millions that debunked COVID-19 misinformation and criticized the government's boosting of traditional medicine as a treatment for the respiratory illness.

Regulators blocked platform Dingxiang Yuan's (DXY) ability to post articles to accounts on popular social media apps including Twitter-like Weibo, WeChat and TikTok's Chinese equivalent Douyin from this week, a source briefed on the matter told Nikkei Asia. The accounts will not be unfrozen without official approval, the source added.

Sponsored Content

About Sponsored ContentThis content was commissioned by Nikkei's Global Business Bureau.